X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AFM24 is a tetravalent, bispecific innate cell engager that binds to CD16A on innate immune cells and EGFR. It is under phase 1/2 clinical development in combination with atezolizumab for the treatment of EGFR-Wildtype Non-Small Cell Lung Cancer.
Lead Product(s): AFM24,Atezolizumab
Therapeutic Area: Oncology Product Name: AFM24
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
AFM24 is a tetravalent, bispecific innate cell engager that activates innate immune system by binding to CD16A on innate immune cells and EGFR. AFM24 in combination with atezolizumab is being evaluated in heavily pre-treated EGFR-wildtype non-small cell lung cancer patients.
Lead Product(s): AFM24,Atezolizumab
Therapeutic Area: Oncology Product Name: AFM24
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
AFM13 (acimtamig), a first-in-class innate cell engager that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors, is being developed in combination with cord blood-derived allogeneic NK cells in patients with Hodgkin lymphoma.
Lead Product(s): Acimtamig,AFM13-NK cells,Cyclophosphamide
Therapeutic Area: Oncology Product Name: AFM13
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: M.D. Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
AFM13 is a first-in-class innate cell engager (ICE®) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors, which is investigated in combination with AlloNK will be investigated for the treatment of relapsed/refractory Hodgkin lymphoma.
Lead Product(s): AFM13,AB-101
Therapeutic Area: Oncology Product Name: AFM13
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
AFM13 is a first-in-class innate cell engager (ICE®) that uniquely leverags the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages to destroy CD30-positive hematologic tumors.
Lead Product(s): AFM13,AB-101
Therapeutic Area: Oncology Product Name: AFM13
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Artiva Biotherapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
AFM28 is a tetravalent bispecific CD123- and CD16A-binding innate cell engager, designed to bring a new immunotherapeutic approach for CD123-positive myeloid malignancies, by engaging NK cells to initiate tumor cell killing via ADCC, even at low CD123 expression levels.
Lead Product(s): AFM28
Therapeutic Area: Oncology Product Name: AFM28
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
AFM13 is a first-in-class innate cell engager (ICE®) that uniquely leverags the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages to destroy CD30-positive hematologic tumors.
Lead Product(s): AFM13
Therapeutic Area: Oncology Product Name: AFM13
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
AFM28, a tetravalent bispecific CD123- and CD16A-binding ICE® developed on Affimed’s ROCK® platform, is designed to bring a new immunotherapeutic approach to patients with CD123-positive myeloid malignancies, including AML and MDS.
Lead Product(s): AFM28
Therapeutic Area: Oncology Product Name: AFM28
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
AFM13 is a first-in-class innate cell engager (ICE®) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors. AFM13 is a tetravalent bispecific innate cell engager designed to act as a bridge between the innate immune cells.
Lead Product(s): AFM13
Therapeutic Area: Oncology Product Name: AFM13
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2022
Details:
Under the terms of the agreement, Affimed and Artiva will pursue the development of the AFM13/AB-101 combination treatment in the United States on a co-exclusive basis. Affimed will lead regulatory activities through Phase 2 and any confirmatory studies.
Lead Product(s): AFM13,AB-101
Therapeutic Area: Oncology Product Name: AFM13
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Artiva Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
